{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-138481","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.112373+00:00","generated_at":"2026-05-19T15:24:37.103049+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sutro Biopharma stockholders approve reverse stock split at 1:5 to 1:25 ratio","bullets":["Reverse stock split authorized at ratio between 1:5 and 1:25, board to set exact ratio.","Three Class I directors elected: Heidi Hunter, Jon Wigginton, Michael Dybbs for three-year terms.","Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 2025 with 99.1% for.","Non-binding advisory vote on named executive officer compensation passed with 42.99M for.","All proposals passed at June 6, 2025 annual meeting; broker non-votes ranged from 12.5M on director elections."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-138481","json":"https://secwatch.observer/filing/0001193125-25-138481.json","markdown":"https://secwatch.observer/filing/0001193125-25-138481.md","text":"https://secwatch.observer/filing/0001193125-25-138481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525138481/0001193125-25-138481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525138481/d859738d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T15:24:37.103049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}